Extended Data Fig. 4: SLAMF6 constrains T cell effector function in vivo.
From: SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer
a-d, Related to Fig. 1e. a, Tumours from the experiment depicted in Fig. 1e were weighed and measured. b-d, Flow cytometry analyses of (b) macrophages (CD11b+F4/80+), (c) neutrophils (CD11b+Ly6G+) and (d) conventional dendritic cells (MHC II+CD11b+) in tumours from mice that received WT or Slamf6−/− OT-I cells. n = 6 mice per group (a-d). e-i, Allogeneic GVHD model. e, Survival and body weight of Balb/c recipients. The mean body weight of the surviving recipients is shown. n = 14 mice per group. f-i, Same as (e), except that mice were followed for 8 days (f,g) or 3 days (h,i). f,h, Survival and body weight of Balb/c recipients monitored for 8 days (f) and 3 days (h), respectively. Donor T cells (H-2Kb+) in recipient spleens were enumerated at day 8 (g) or day 3 (i) post-transplantation; CD44hi donor T cells were quantified at day 8 (g). n = 7 (WT donor T cells), 6 (Slamf6−/− donor T cells) and 6 (PBS) in f,g. n = 7 (WT donor T cells), 7 (Slamf6−/− donor T cells) and 5 (PBS) in h,i. Each symbol in a-d,g,i represents a mouse; error bars represent mean ± s.d. For survival analyses, a log-rank (Mantel-Cox) test was performed (e,f,h). Otherwise, two-sided unpaired Student’s t-test were used (a-d,g,i). Numbers above data points or next to line charts represent p values. Results are pooled from 2 (a-d) or 3 (e-i) independent experiments.
